CLAIMS

1. A therapeutically effective amount of an antiviral agent comprising valacyclovir, acyclovir, famciclovir, pritelivir, ganciclovir, glycyrrhizic acid, sambucus nigra, or valganciclovir, or a salt, solvate or combination thereof for use in a method of pre-exposure prophylaxis against HSV infection in an HSV seronegative subject, in which the antiviral agent is to be orally administered to the subject prior to sexual contact with a partner who is seropositive for HSV.

2. An antiviral agent for use according to Claim 1, in which the therapeutically effective amount of the antiviral agent is from 5 mg to 2000 mg.

3. An antiviral agent for use according to Claim 1 or 2, in which the therapeutically effective amount of the antiviral agent is from 500 mg to 2000 mg.

4. An antiviral agent for use according to Claim 1, 2 or 3, in which a therapeutically effective amount of an additional antiviral agent is to be administered to the subject.

5. An antiviral agent for use according to Claim 4, in which the additional antiviral agent is an HIV antiviral agent.

6. An antiviral agent for use according to Claim 5, in which the HIV antiviral agent comprises tenofovir, emtricitabine, lamivudine, efavirenz, raltegravir, dolutegravir, maravoric, rilpirivine, or a salt, solvate or combination thereof.

7. An antiviral agent for use according to any preceding claim, in which an effective amount of a contraceptive is further to be administered to the subject.

8. An antiviral agent for use according to Claim 7, in which the contraceptive comprises levonorgestrel, estradiol, dosogestrel, ethinyl estradiol, norethindrone acetate, norgestimate, or a salt, solvate or combination thereof.